New Merck pneumococcal vaccine wins FDA approval
STAT
JUNE 17, 2024
The Food and Drug Administration on Monday approved Merck’s new pneumococcal vaccine for adults 18 and older.
Trying to time your seasonal vaccines just right? There are no easy answers, but here are some factors to consider
STAT
SEPTEMBER 4, 2024
The standard advice — get your shots, get them at the same time, don’t wait too long to roll up your sleeves — is designed to maximize convenience and compliance, in a way that is manageable for the delivery enterprise, say experts familiar with the enormous effort it takes to turn vaccines into vaccinations.
Vaccines 
363
363 Join 11,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: Cancer vaccine startup launches with $54 million, Spark veteran as CEO
STAT
APRIL 18, 2024
A new startup focused on creating vaccines for cancers, influenza, and potentially even HIV launched Thursday with $54 million in funding. Altschuler and Ziff’s relationship goes back to the mid-2010s, when Altschuler was chief executive of the well-known research hospital Children’s Hospital of Philadelphia, or CHOP.
Vaccines 320
320 
STAT+: Moderna plans to follow in Pfizer’s footsteps, charge up to $130 for Covid-19 vaccine in U.S.
STAT
JANUARY 9, 2023
Moderna disclosed Monday that it plans to price its Covid-19 vaccine at anywhere from $110 to $130 per dose when the company pivots from a focus on government contracts to commercial distribution efforts. The timing was not disclosed, but the company is holding talks with hospitals, pharmacy chains and pharmacy benefit managers.
Vaccines 255
255 
Respiratory vaccination candidate tested in German hospitals
Pharma Times
DECEMBER 1, 2022
Novel tuberculosis vaccine tested in a large phase 3 trial against severe respiratory infection disease
Vaccines 142
142 
STAT+: Pharmalittle: FDA OKs first RSV vaccine for older adults; Lilly Alzheimer’s data puts pressure on Medicare
STAT
MAY 4, 2023
Food and Drug Administration licensed the first-ever vaccine for respiratory syncytial virus, or RSV , completing an elusive quest that has been decades in the making , STAT writes. A vaccine that was developed by Pfizer and aimed at the same demographic is expected to be approved by the end of the month.
Vaccines 237
237 
UKHSA urges individuals from ethnic minority groups to get vaccinated
Pharma Times
DECEMBER 11, 2023
New data highlights the inequalities in emergency hospital rates and vaccinations - News - PharmaTimes
Vaccines 158
158 
F.D.A. Aims to Give Final Approval to Pfizer Vaccine by Early Next Month
NY Times
AUGUST 3, 2021
The Food and Drug Administration’s move is expected to kick off more vaccination mandates for hospital workers, college students and federal troops.
Vaccines 145
145 
Pfizer Vaccine Protection Wanes, C.D.C. Study Shows
NY Times
SEPTEMBER 17, 2021
The study found that the shots’ effectiveness in preventing hospitalization fell to 77 percent from 91 percent four months after full vaccination.
Vaccines 105
105 
F.D.A. Fully Approves Pfizer Vaccine
NY Times
AUGUST 23, 2021
The move was expected to kick off a round of new vaccination mandates from hospitals, schools and private companies.
Vaccines 98
98 
Approval-first for meningococcal vaccine
European Pharmaceutical Review
OCTOBER 24, 2023
PENBRAYA (meningococcal groups A, B, C, W and Y vaccine), the first and only pentavalent vaccine that provides the broadest serogroup coverage of any meningococcal vaccine available in the US for meningococcal disease in individuals aged 10 to 25 years old, has been approved by the US Food and Drug Administration (FDA).
Vaccines 105
105 
How advanced technology can streamline the COVID-19 vaccine rollout
pharmaphorum
MARCH 2, 2021
Zebra Technologies healthcare lead Chris Sullivan discusses the COVID-19 vaccine rollout and how technology can streamline the process to combat new variants. . While the rollout of the COVID-19 vaccine has signified the first signs of light at the end of the tunnel, the reality is that this public health crisis is still far from over.
Vaccines 119
119 
Indian Immunologicals partners with ICMR for clinical development of India’s first Zika vaccine
Express Pharma
SEPTEMBER 12, 2024
Indian Immunologicals (IIL), a vaccine manufacturer, has signed a Memorandum of Agreement (MoA) with the Indian Council of Medical Research (ICMR) to develop India’s first codon de-optimized live attenuated Zika vaccine. Currently, no vaccine is available for Zika prevention.
Vaccines 105
105 
IIT Mandi researchers propose a protein-based vaccine against pork tapeworm
Express Pharma
SEPTEMBER 26, 2023
Indian Institute of Technology Mandi researchers, led by Dr Amit Prasad, Associate Professor, School of Biosciences and Bioengineering, has made strides in the development of vaccines against the pork tapeworm (T. Traditionally, tapeworm vaccines have been developed using products or antigens derived from tapeworm eggs or larvae.
Vaccines 111
111 
Trials of Valneva COVID-19 vaccine begin in UK
pharmaphorum
DECEMBER 17, 2020
Trials of a fifth COVID-19 vaccine have begun in the UK, as IT issues threaten to delay the roll-out of the shot from Pfizer/BioNTech. France’s Valneva begun the phase 1/2 clinical study of the inactivated vaccine candidate VLA2001 in sites across the UK, supported by the National Institute for Health Research (NIHR).
Vaccines 105
105 
New vaccine trial hopes to offer 'breakthrough' in fight against Zika
The Pharmacist
MAY 4, 2023
A ground-breaking trial of a new Zika vaccine has started, with the first participant receiving the dose at the Royal Liverpool University Hospital, in conjunction with ongoing research at the universities of Liverpool and Manchester.
Vaccines 95
95 
FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel
pharmaphorum
DECEMBER 9, 2020
Reviewers from the FDA have given their blessing to the Pfizer/BioNTech COVID-19 vaccine ahead of a key meeting tomorrow – but the regulator noted that there are still uncertainties about whether the shot can stop the disease from spreading. The post FDA reviewers back Pfizer/BioNTech COVID-19 vaccine ahead of panel appeared first on.
Vaccines 111
111 
What You Need to Know About the New COVID-19 Vaccines
Community Pharmacy
OCTOBER 27, 2023
While COVID-19 might not be as pressing of a problem as it was during the peak of the pandemic, the virus and its many variants still pose significant health risks that require updated vaccine protection to combat. rise, which previous year’s vaccines were not designed to protect against.
Vaccines 105
105 
Development of universal influenza vaccines gaining precedence: GlobalData
Express Pharma
JUNE 15, 2023
The current influenza vaccines only provide protection against a limited number of strains, with the strains predicted to be dominant in the upcoming season selected for inclusion in the vaccines. Ultimately one of the biggest benefits of a universal influenza vaccine is that it could help to contain a potential pandemic.”
Vaccines 98
98 
Early data shows Russia’s Sputnik V COVID-19 vaccine produces immune response
pharmaphorum
SEPTEMBER 7, 2020
A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. The vaccine also produced a T-cell response within 28 days, a secondary outcome.
Immunity 107
107 
Data hackathon analyses truth behind TB vaccine and COVID-19
pharmaphorum
OCTOBER 23, 2020
Is a century-old vaccine a ‘game-changer’ for COVID-19? This is especially true in the search for effective therapies to fight COVID-19, and a vaccine. In a worst-case scenario, misplaced hype could lead to a sudden rush to buy doses of the BCG vaccine. Understanding the link between COVID-19 and the BCG vaccine.
Vaccines 110
110 
Digital innovation drives vaccine development
pharmaphorum
JANUARY 31, 2022
It is becoming increasingly important for people all over the world to understand the importance of vaccines and to have access to the vaccines they need – especially with digital innovation driving new vaccine development. Pfizer’s Josh Raysman, Saad Saeed, and Shanaya Deboo discuss vaccine awareness, access, and innovation.
Vaccines 97
97 
UK gears up for ‘challenge trial’ of COVID-19 vaccine
pharmaphorum
SEPTEMBER 24, 2020
The UK could be the first country to carry out a COVID-19 “challenge trial” where healthy volunteers are deliberately infected with coronavirus to test vaccines, according to press reports. That vaccine is top of the World Health Organization’s list of vaccines in clinical development, which shows there are 38 potential shots in human trials.
Vaccines 98
98 
What HCPs think about blood clots linked to COVID-19 vaccines
pharmaphorum
JUNE 2, 2021
In the latest edition of What HCPs Think , CREATION.co’s Laura Marsh looks at what healthcare professionals are saying about blood clots linked to COVID-19 vaccines. This sudden increase is due to reports of rare blood clots in recipients of the COVID-19 vaccines developed by AstraZeneca and more recently Johnson & Johnson.
Vaccines 105
105 
Bomb scare sparks evacuation of plant making AZ COVID-19 vaccine
pharmaphorum
JANUARY 27, 2021
A plant in Wales manufacturing the AstraZeneca COVID-19 vaccine was evacuated on the advice of the authorities today after it was sent a suspicious package. The contract covers production of 100 million doses of the AZ vaccine. Wockhardt UK in Wrexham this morning received a suspicious package.
Vaccines 98
98 
Shingles vaccine reduces risk of stroke and heart attack from virus: Study
Express Pharma
JULY 26, 2023
Results are based on analysis of data from 278,375 adults in New Zealand who got the vaccine between April 2018 and July 2021. Most were aged 70 or older Getting vaccinated against shingles could significantly reduce the risk of suffering a stroke or heart attack from the virus, a new study has found. Most were aged 70 or older.
Vaccines 98
98 
First COVID-19 vaccinations begin in UK hospitals
pharmaphorum
DECEMBER 8, 2020
A 90-year-old woman has become the first person given a COVID-19 vaccine as part of the UK’s mass vaccination programme. Margaret Keenan was given the injection at 06:31 this morning at University Hospitals Coventry and Warwickshire NHS Trust. The post First COVID-19 vaccinations begin in UK hospitals appeared first on.
Hospitals 52
52 
AZ starts phase 2/3 trial of new-variant COVID-19 vaccine
pharmaphorum
JUNE 27, 2021
AstraZeneca and Oxford University have started dosing patients in a trial of a new version of their COVID-19 vaccine that is designed to target the beta or South African variant of the SARS-CoV-2 virus. The post AZ starts phase 2/3 trial of new-variant COVID-19 vaccine appeared first on. The beta variant – also known as B.1.351
Vaccines 101
101 
RSV Vaccination Could Decrease Hospitalization Among Adults 60 Years and Older
Pharmacy Times
SEPTEMBER 6, 2024
RSV vaccination was 75% effective in preventing RSV-associated hospitalizations among adults aged 60 years and older.
Hospitals 48
48 
RSV Vaccine Displays Effectiveness Against RSV-Associated Hospitalizations
Pharmacy Times
NOVEMBER 13, 2024
RSV vaccination is approximately 77% to 81% effective against hospital and emergency department encounters among older adults.
Hospitals 44
44 
Researchers Assess Burden of RSV Hospitalization Prior to Vaccine Introduction
Pharmacy Times
NOVEMBER 14, 2024
Increasing vaccine coverage among adults at highest risk could lessen associated hospitalizations and severe outcomes caused by RSV.
Hospitals 45
45 
AZ COVID-19 vaccine cleared in UK, dosing to start next week
pharmaphorum
DECEMBER 30, 2020
The UK has approved AstraZeneca and Oxford University’s COVID-19 vaccine AZD1222 in another significant step forward in the fight against the pandemic, with first doses due to be administered on Monday. The #coronavirus vaccine is our way out of the pandemic – now we need to hold our nerve while we get through this together.
Vaccines 98
98 
Updated BNT162b2 XBB COVID-19 Vaccine Protects Against Hospitalization in Children Aged 5 to 17
Pharmacy Times
DECEMBER 28, 2024
Study results show that the updated BNT162b2 XBB vaccine is effective in preventing hospitalizations or emergency department visits associated with COVID-19 complications.
Hospitals 49
49 
Does the pandemic mark a turning point in vaccine development?
pharmaphorum
MARCH 11, 2022
After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.
Vaccines 81
81 
Moderna Bivalent COVID-19 Vaccine More Effective at Preventing Hospitalization in High-Risk Patients Compared With Pfizer-BioNTech Vaccine
Pharmacy Times
NOVEMBER 8, 2024
Though both vaccines remain effective at preventing severe illness, Moderna’s mRNA-1273.222 vaccine was found to be significantly more effective among adults with underlying medical conditions.
Vaccines 52
52 
Advancing research on human immune systems in India to develop better vaccines
Express Pharma
JUNE 20, 2023
The vaccine efforts of the COVID-19 pandemic highlighted our knowledge about gaps in the immune system. Similarly, institutes that facilitate connections between local hospitals and research institutes play an essential role. However, the spotlight has shifted to unravelling the complexities of the human immune system.
Immunity 105
105 
FDA Approves Moderna’s and Pfizer/BioNTech’s Updated COVID-19 Vaccines
Big Molecule Watch
SEPTEMBER 3, 2024
On August 22, Moderna announced that FDA approved its supplemental Biologics License Application (“sBLA”) for a new formula of their COVID-19 vaccine, SPIKEVAX®, for individuals 12 years old and above. Emergency Use Authorization (“EUA”) was also granted for the updated vaccine for individuals aged 6 months to 11 years old.
Vaccines 59
59 
Nirmatrelvir-Ritonavir Has Little Impact on COVID-19 Hospitalization, Mortality in Vaccinated Older Adults
Pharmacy Times
MARCH 3, 2025
New results shed light on the ineffectiveness of the combination antiviral therapy in patients vaccinated against COVID-19.
Vaccines 52
52 
Unpacking Precision Vaccines with Nicole Lewis (World Vaccine Conference 2023)
PharmaTech
APRIL 6, 2023
Nicole Lewis, PVP Program Manager at Boston Children's Hospital, discusses the science behind precision vaccines, a form of personalized vaccines.
Vaccines 52
52 
As the Prospect of a Vaccine Approaches, Business and Communications Challenges Are Just Around the Corner
Eye on FDA
NOVEMBER 17, 2020
Coincident to COVID-19 case levels in Europe and the United States entering new and serious levels comes welcome news on the development of a vaccine. While vaccination may actually begin in December, the number of doses will be limited. In addition, the process of vaccination takes time.
Vaccination Coverage in Patients With Diabetes
Pharmacy Times
AUGUST 30, 2022
Hospitalization and interprofessional team management, particularly the involvement of a pharmacist, are essential in vaccination coverage for patients with diabetes.
Diabetes 52
52 
Indian Immunologicals rolls out India’s first indigenously developed Hepatitis A Vaccine ‘Havisure’
Express Pharma
JANUARY 20, 2024
Indian Immunologicals has launched Hepatitis A vaccine “Havisure”. It is a two-dose vaccine wherein the first dose is administered at above 12 months of age and the second dose is given at least after 6 months of the first dose. The vaccine is comparable to the world’s leading vaccine sold by a multinational.
Vaccines 59
59 
Vaccination Rates Among Children May Be Impacted by Safety Concerns
Pharmacy Times
OCTOBER 5, 2022
Vaccines reduce the risk of COVID-19 infection and hospitalization, but a recent study suggests that misinformation could make adults hesitant to vaccinate children 5 to 11 years of age.
Vaccines 52
52 
EC grants marketing authorisation for Takeda’s dengue vaccine
Pharmaceutical Technology
DECEMBER 9, 2022
The European Commission (EC) has granted marketing authorisation for Takeda ’s Qdenga (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) to prevent dengue in people aged four years and above. According to the results, the trial met the primary endpoint of overall vaccine efficacy by averting 80.2%
Vaccines 59
59 
Let's personalize your content